|
|
|
|
6 Indian firms to boost supply of remdesivir by Gilead
|
|
|
|
| Top Stories |
 |
|
|
|
SME Times News Bureau | 14 Jun, 2020
Over a course of about one month, US drug-maker Gilead Sciences has
signed non-exclusive voluntary licensing agreements with at least six
Indian pharmaceutical companies to boost the supply of remdesivir, the
experimental antiviral drug that has shown promise in Covid-19
treatment.
These companies are -- Dr. Reddy's Laboratories Ltd.,
Zydus Cadila Healthcare Ltd., Biocon company Syngene, Hetero Labs Ltd.;
Jubilant Lifesciences; and Cipla Ltd.
In addition, Gilead said
it had signed a similar agreement with US-based Mylan which has a strong
India presence and Egypt-based Eva Pharma and Pakistan-based Ferozsons
Laboratories.
The agreements allow these companies to manufacture remdesivir for distribution in 127 countries.
The regulatory approval status of remdesivir varies by country.
The Union Health Ministry in India on Saturday recommended use of remdesivir in Covid-19 patients in moderate stage.
Under
the licensing agreements, the companies have a right to receive a
technology transfer of the Gilead manufacturing process for remdesivir
to enable them to scale up production more quickly.
The licensees also set their own prices for the generic product they produce.
The
licenses are royalty-free until the World Health Organization declares
the end of the Public Health Emergency of International Concern
regarding COVID-19, or until a pharmaceutical product other than
remdesivir or a vaccine is approved to treat or prevent COVID-19,
whichever is earlier, Gilead said.
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Customs Exchange Rates |
| Currency |
Import |
Export |
US Dollar
|
84.35
|
82.60 |
UK Pound
|
106.35
|
102.90 |
Euro
|
92.50
|
89.35 |
| Japanese
Yen |
55.05 |
53.40 |
| As on 12 Oct, 2024 |
|
|
| Daily Poll |
 |
 |
| Will the new MSME credit assessment model simplify financing? |
|
|
|
|
|
| Commented Stories |
|
|
|
|
|
|
| |
|
